Bayer sets cautious price for Agfa IPO:
This article was originally published in Clinica
Executive Summary
Bayer has set a price range of between E 21 and E 26 ($22.4 and $27.7) for the initial public offering of up to 55% of its Agfa imaging division - valuing the transaction at between $1.6 billion and $1.9 billion. The price has been described as cautious by analysts. Separately, Belgian holding company Gevaert will acquire a 15% share of the company with an option to buy a further 10% after a year. Trading in Agfa shares will begin on June 1 on the Frankfurt and Brussels stock exchanges.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.